Search

Michael A Clayman

from Tucson, AZ
Age ~89
Get Report
Also known as:
Mike Clayman, Michae Clayman, Michael N
Phone and address:
6199 E Broadway Blvd, Tucson, AZ 85711
Related to:
Kelly Turlo, 35Dale Turlo, 71Frank E Turlo, 77Brigette Martinez, 38Hilda Martinez, 75Eric Swenson, 82
Connected to:
Alisyn J Clayman, 47Bradly R Clayman, 34Eldon L Clayman, 82Hannah S Clayman, 34Linda A Clayman, 81Marcie L Clayman, 72Rebecca H Clayman, 35Terri F Clayman, 70Julie A Claymiller, 58Michelle A Claymore, 58

Michael Clayman Phones & Addresses

  • 6199 E Broadway Blvd, Tucson, AZ 85711
  • 104 Parker Ter, North Easton, MA 02356 (508) 297-1338
  • 24 Central St #3, South Easton, MA 02375
  • Easton, MA
  • Randolph, MA
  • N Easton, MA
  • Brockton, MA
  • 6199 E Broadway Blvd APT 219, Tucson, AZ 85711

Professional Records

License Records

Michael Douglas Clayman

License #:
MT008083T - Expired
Category:
Medicine
Type:
Graduate Medical Trainee

Resumes

Resumes

Michael Clayman Photo 1

Ceo At Flexion Therapeutics, Inc.

View page
Location:
Greater Boston Area
Industry:
Biotechnology
Michael Clayman Photo 2

Michael Clayman

View page
Michael Clayman Photo 3

Michael Clayman

View page
Michael Clayman Photo 4

Michael Clayman

View page
Michael Clayman Photo 5

Michael Clayman

View page
Location:
Greater Boston Area
Industry:
Publishing
Michael Clayman Photo 6

Michael Clayman

View page
Location:
United States

Business Records

Name / Title
Company / Classification
Phones & Addresses
Michael G. Clayman
President
HHC PUBLISHING, INC
42 Old Wolomolopoag St, Norwood, MA 02062
42 Old Wolomolopoag St, Sharon, MA 02067
Michael D. Clayman
President
FLEXION THERAPEUTICS SECURITIES CORPORATION
Pharmaceutical Preparations
10 Mall Rd, Burlington, MA 01803
10 Mall Rd - STE 301, Burlington, MA 01803
Michael S. Clayman
THE DAVID NATHAN CLAYMAN CO., LLC

Publications

Us Patents

Corticosteroids For The Treatment Of Joint Pain

View page
US Patent:
20120282298, Nov 8, 2012
Filed:
Feb 8, 2012
Appl. No.:
13/368580
Inventors:
Neil Bodick - Boston MA, US
Robert C. Blanks - Auburndale MA, US
Anjali Kumar - Belmont MA, US
Michael D. Clayman - Gloucester MA, US
Mark Moran - Orinda CA, US
International Classification:
A61K 31/58
A61P 25/00
A61P 29/00
A61K 9/14
US Classification:
424400, 514174
Abstract:
Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.

Corticosteroids For The Treatment Of Joint Pain

View page
US Patent:
20120288534, Nov 15, 2012
Filed:
Mar 16, 2012
Appl. No.:
13/422994
Inventors:
Neil Bodick - Boston MA, US
Robert C. Blanks - Auburndale MA, US
Anjali Kumar - Belmont MA, US
Michael D. Clayman - Gloucester MA, US
Mark Moran - Orinda CA, US
International Classification:
A61K 31/56
A61P 19/02
A61P 29/00
A61K 31/58
A61K 9/14
US Classification:
424400, 514174, 514179
Abstract:
Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.

Corticosteroids For The Treatment Of Joint Pain

View page
US Patent:
20180311260, Nov 1, 2018
Filed:
Mar 27, 2018
Appl. No.:
15/937053
Inventors:
- Burlington MA, US
Robert C. Blanks - Auburndale MA, US
Anjali Kumar - Belmont MA, US
Michael D. Clayman - Burlington MA, US
Mark Moran - Orinda CA, US
International Classification:
A61K 31/58
A61K 9/14
A61K 31/573
A61K 47/34
A61K 9/16
A61K 9/00
Abstract:
Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.

Corticosteroids For The Treatment Of Joint Pain

View page
US Patent:
20170182068, Jun 29, 2017
Filed:
Mar 15, 2017
Appl. No.:
15/459961
Inventors:
- Burlington MA, US
Robert C. Blanks - Auburndale MA, US
Anjali Kumar - Belmont MA, US
Michael D. Clayman - Burlington MA, US
Mark Moran - Orinda CA, US
International Classification:
A61K 31/58
A61K 9/16
A61K 9/00
Abstract:
Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.

Corticosteroids For The Treatment Of Joint Pain

View page
US Patent:
20170135957, May 18, 2017
Filed:
Jan 31, 2017
Appl. No.:
15/420829
Inventors:
- Burlington MA, US
Robert C. Blanks - Auburndale MA, US
Anjali Kumar - Belmont MA, US
Michael D. Clayman - Gloucester MA, US
Mark Moran - Orinda CA, US
International Classification:
A61K 9/16
A61K 31/573
A61K 31/58
A61K 9/00
Abstract:
Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.

Corticosteroids For The Treatment Of Joint Pain

View page
US Patent:
20150025050, Jan 22, 2015
Filed:
Aug 18, 2014
Appl. No.:
14/461883
Inventors:
- Burlington MA, US
Robert C. Blanks - Auburndale MA, US
Anjali Kumar - Belmont MA, US
Michael D. Clayman - Gloucester MA, US
Mark Moran - Orinda CA, US
International Classification:
A61K 31/58
A61K 47/34
US Classification:
514174
Abstract:
Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.

Corticosteroids For The Treatment Of Joint Pain

View page
US Patent:
20140356437, Dec 4, 2014
Filed:
Aug 18, 2014
Appl. No.:
14/461884
Inventors:
- Burlington MA, US
Robert C. Blanks - Auburndale MA, US
Anjali Kumar - Belmont MA, US
Michael D. Clayman - Gloucester MA, US
Mark Moran - Orinda CA, US
International Classification:
A61K 31/58
A61K 31/573
A61K 9/14
US Classification:
424489, 514174, 514180
Abstract:
Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.

Corticosteroids For The Treatment Of Joint Pain

View page
US Patent:
20140242170, Aug 28, 2014
Filed:
Dec 16, 2013
Appl. No.:
14/107188
Inventors:
- Burlington MA, US
Robert C. Blanks - Auburndale MA, US
Anjali Kumar - Belmont MA, US
Michael D. Clayman - Gloucester MA, US
Mark Moran - Orinda CA, US
Assignee:
FLEXION THERAPEUTICS, INC. - Burlington MA
International Classification:
A61K 31/58
US Classification:
424486, 514174
Abstract:
Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
Control profile
Michael A Clayman from Tucson, AZ, age ~89 Get Report